ZP
SPRY icon

Zimmer Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Zimmer Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$436K – 217
2021
Q1 		$436K Hold
10,000
– – 0.01% 158
2020
Q4 		$463K Buy
+10,000
New +$334K 0.01% 117

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Zimmer Partners's SPRY Position: Q2 2021 in Review

Zimmer Partners sold out of ARS Pharmaceuticals (SPRY) in Q2 2021, closing a stake of 10,000 shares — an estimated $436K sold.

Zimmer Partners first reported a position in SPRY in Q4 2020 and held it in 2 quarters. The position peaked at $463K in Q4 2020. 76 funds tracked by Wall St. Rank hold SPRY as of Q2 2021.

  • Zimmer Partners reported no remaining ARS Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Zimmer Partners sold 10,000 ARS Pharmaceuticals shares in Q2 2021, an estimated $436K.
  • Zimmer Partners first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Zimmer Partners's ARS Pharmaceuticals position peaked at $463K in Q4 2020.
  • 76 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2021.

Based on Zimmer Partners's 13F filing for Q2 2021, filed 16 Aug 2021.